Prosecution Insights
Last updated: October 27, 2026

Paul Ellsworth Hoerner, USPTO Patent Examiner

Listed by the USPTO as HOERNER, PAUL ELLSWORTH

Tech Center 3700 • Art Units: 1611 1645 3774

This examiner grants 51% of resolved cases

Analysis

Paul Ellsworth Hoerner works in Tech Center 3700 and Art Unit 1611. He has 83 resolved cases and an allowance rate of 50.6%. The median time to allowance is 1341 days. The interview lift is 62.3%, which is a very high increase over the baseline allowance rate.

Mind Medicine Inc., L'Oréal, and SUMITOMO CHEMICAL Company, Limited are top applicants. COOLEY LLP, OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and pH IP Law are the leading firms. The 50.6% allowance rate suggests a moderate level of difficulty, but the 62.3% interview lift indicates that direct communication is exceptionally effective. The 1341 days median pendency is a key factor for applicants to consider. With 83 resolved cases, the examiner has a developing record in chemical and pharmaceutical technology.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

50.6%
Allow Rate
-19.4% vs TC avg
127
Total Applications
+62.3%
Interview Lift
1341
Avg Prosecution Days
Based on 83 resolved cases, 2023–2026

Rejection Statute Breakdown

1.6%
§101 Eligibility
12.3%
§102 Novelty
48.2%
§103 Obviousness
21.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17600843 LIPID NANOPARTICLES AS ORAL VEHICLES OF IMMUNOTHERAPY Final Rejection The Johns Hopkins University
18847255 PEROXIDE HYDROGEL COMPOSITIONS AND THEIR USE FOR FIBER BLEACHING Non-Final OA HENKEL AG & CO. KGAA
18719164 METHODS FOR DESIGNING AND PERFORMING A VAPOR PHASE HYDROGEN PEROXIDE DECONTAMINATION CYCLE Final Rejection Amgen Inc.
17819268 DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18827288 SPHERICAL AGGLOMERATION OF PROTEINS Non-Final OA Purdue Research Foundation
18723132 IRON OXIDE NANOPARTICLE-MEDIATED RADIATION DELIVERY FOR TARGETED CANCER TREATMENT Non-Final OA University of Washington
18257983 COSMETIC COMPOSITION COMPRISING A COMBINATION OF TWO PARTICULAR COUPLERS AND A NONIONIC SURFACTANT OF ALKYLPOLYGLYCOSIDE TYPE Final Rejection L'OREAL
17311260 TOPICAL COMPOSITION COMPRISING VIABLE MICROORGANISMS Final Rejection L'Oreal S.A.
18715218 Personal Care Compositions Non-Final OA Colgate-Palmolive Company
18987772 WEED CONTROL METHOD Non-Final OA SUMITOMO CHEMICAL COMPANY, LIMITED
18255000 PESTICIDAL COMPOSITION Final Rejection SUMITOMO CHEMICAL COMPANY, LIMITED
17434299 MICROWAVE ASSISTED EXTRACTION OF ESSENTIAL OILS FROM PLANT BIOMASS Non-Final OA FIRMENICH SA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Paul Ellsworth Hoerner's allowance rate?

50.6% of resolved applications examined by Paul Ellsworth Hoerner were allowed (83 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.

Does an interview help with examiner Paul Ellsworth Hoerner?

This examiner's interview lift is +62.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Paul Ellsworth Hoerner take to allow a patent?

Applications allowed by Paul Ellsworth Hoerner took 1,341 days on average from filing to allowance.

Which art unit does examiner Paul Ellsworth Hoerner work in?

Paul Ellsworth Hoerner examines applications in Art Unit 1611 in Tech Center 3700 (Medical Devices & Mechanical Engineering).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month